Search

Displaying results 3231 - 3240 of 7897 in total
  1. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. … Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing

  2. Drug

    Chromium picolinate

    go.drugbank.com/drugs/DB11255
    Approved

    Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. … Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss.

    Mixtures: Medi TabCategories: Compounds used in a research, industrial, or household setting
  3. Drug

    Ceforanide

    go.drugbank.com/drugs/DB00923
    Approved

    It has a longer elimination half-life than any currently available cephalosporin. … Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species

  4. Drug

    Sennosides

    go.drugbank.com/drugs/DB11365
    ApprovedInvestigational

    Sennosides (also known as senna glycoside or senna) is a medication used to treat constipation[FDA Label][L771] and empty the large intestine before surgery. … It is a weaker laxative than bisacodyl or castor oil[A177092].

    Salts: Sennosides A and BProducts: B-QNYS, Glysennid Tab 8.6mg
  5. Drug

    Dexlansoprazole

    go.drugbank.com/drugs/DB05351
    Approved

    Dexlansoprazole is the R-enantiomer of [DB00448], which is composed of a racemic mixture of the R- and S-enantiomers. … release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing.

  6. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. … As of February 2007 the development of AZD3409 had been discontinued.

  7. Drug

    SF1126

    go.drugbank.com/drugs/DB05210
    Investigational

    SF1126 is an integrin-targeted PI3 kinase inhibitor.

  8. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    Concizumab is a humanized IgG4 monoclonal antibody targeting the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), a key regulator of the coagulation cascade. … [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.

  9. Drug

    Tecadenoson

    go.drugbank.com/drugs/DB04954
    Investigational

    Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.

  10. Drug

    Secretin human

    go.drugbank.com/drugs/DB09532
    ApprovedInvestigational

    Purified synthetic human secretin, also referred to as RG1068, is available as an intravenous injection under the market name ChiRhoStim ® in the U.S.. … Although it is a gastrointestinal hormone, secretin is also considered as a neuropeptide hormone since it is also expressed in the central nervous system [A32275].